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ABSTRACT
Objectives: Animal studies and clinical trials have
examined the potential beneﬁts of statins in asthma
management with contradictory results. The
objective of this study was to determine if asthma
patients on concurrent statins are less likely to have
asthma-related hospitalisations.
Design: A retrospective cohort study using Mississippi
Medicaid data for 2002e2004.
Participants: Asthma patients $18 years were
identiﬁed using the ICD9 code 493.xx from 1 July 2002
through 31 December 2003. The index date for an
exposed subject was any date within the identiﬁcation
period, 180 days prior to which the subject had at least
one inhaled corticosteroid prescription and at least an
80% adherence rate to statins. Asthma patients on
inhaled corticosteroids, but not on statins, were selected
as the unexposed population. The two groups were
matched and followed for 1 year beginning the index date.
Main outcomes measures: Patient outcomes in
terms of hospitalisations and ER visits were compared
using conditional logistic regression.
Results: After matching, there were 479 exposed
subjects and 958 corresponding unexposed subjects.
The odds of asthma-related hospitalisation and/or
emergency room (ER) visits for asthma patients on
concurrent statins were almost half the odds for
patients not on statins (OR¼0.55; 95% CI (0.37 to
0.84); p¼0.0059). Similarly, the odds of asthma-
related ER visits were signiﬁcantly lower for patients
on statins (OR¼0.48; 95% CI (0.28 to 0.82);
p¼0.0069).
Conclusion: The ﬁndings suggest beneﬁcial effects of
statins in asthma management. Further prospective
investigations are required to provide more conclusive
evidence.
INTRODUCTION
Inhibitors of 3-hydroxy-3-methylglutaryl
coenzymes A (HMG CoA) reductase, that is,
statins are conventionally prescribed as anti-
hyperlipidemics. In the past decade, they
have been shown to have promising thera-
peutic potential in mediating inﬂammatory
processes.
1e5 Statins have been shown to be
effective in animal model studies as well as
clinical trials of rheumatoid arthritis,
6e8
autoimmune encephalomyelitis,
91 0inﬂam-
matory colitis
11 12 and even psoriasis
13 due to
their anti-inﬂammatory properties. A recent
observational study reported a striking 41%
reduction in mortality (OR, 0.59; 95% CI
0.38 to 0.92) in persons on statins either
prior to or during hospitalisation with inﬂu-
enza infection.
14 Given this, there has been
some discussion pertaining to the use of
statins in the management of asthma.
15e19
Animal model studies using rats suggest that
systemic lovastatin inhibits antigen-induced
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ARTICLE SUMMARY
Article focus
- Statins have been shown to have promising
therapeutic potential in mediating anti-inﬂamma-
tory processes in animal model studies as well as
clinical trials of rheumatoid arthritis, autoimmune
encephalomyelitis, inﬂammatory colitis and
psoriasis.
- Along the same line of reasoning, recently there
has been some discussion regarding the use of
statins in asthma management in addition to
inhaled corticosteroid therapy.
- The purpose of this study was to investigate the
beneﬁcial effects of statins on asthma outcomes
using the Mississippi Medicaid claims database.
Key messages
- The ﬁndings suggest that statins may be
beneﬁcial in asthma management.
- The study accounts for several additional poten-
tial confounders not previously explored in the
other observational studies.
Strengths and limitations of this study
- The study uses a propensity score-matched
cohort study design, which in itself should take
into account potential confounding effects.
- The study was conducted using Medicaid claims
data, and therefore, there is a possibility of
misclassiﬁcation due to coding errors during
claims processing.
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Open Access Researchbronchial smooth muscle hyper-responsiveness.
20 It also
reduces the increased cell number in bronchoalveolar
lavage ﬂuids and histological changes induced by antigen
exposure. Levels of immunoglobulin E in sera and
interleukins -4, -6 and -13 in the bronchoalveolar lavage
ﬂuids did not change signiﬁcantly. Similar experiments
have been conducted with mice
21 22 with ﬁndings that
support the beneﬁcial role of statins in asthma manage-
ment. The proposed mechanism of action for this
observation is that statins inhibit the geranylgeranylation
of a monomeric GTP-binding protein RhoA and its
downstream metabolites, which are involved in the
agonist-induced Ca
2+ sensitisation of airway smooth
muscle contraction. The RhoA/RhoA kinase pathway is
now being investigated as the new target for the treatment
of airway hyper-responsiveness. A study conducted by
McKay and colleagues
23 showed the inhibitory effects of
simvastatin on inﬂammatory cell inﬁltration in a murine
model of allergic asthma. Similar experiments have been
conducted with pravastatin and simvastatin, the results of
which suggest asthma management to be an emerging
indication for statins.
24e26
Apart from the animal model studies described above,
four small-scale clinical trials have been conducted with
mixed results. A randomised double-blind crossover
placebo-controlled trial investigated the effect of oral
atorvastatin on measures of asthma control and airway
inﬂammation.
27 The trial included 54 adults with
allergic asthma receiving inhaled corticosteroids alone.
The authors found no clinically important improve-
ments in a range of clinical indices of asthma control
measures despite expected changes in serum lipids.
They concluded that statins were ineffective for the
short-term therapy of asthmatic inﬂammation. However,
a change in the airway inﬂammation as well as a reduc-
tion in the sputum macrophage count was observed
indicating that statins could have beneﬁcial effects in
other chronic lung diseases. A similar clinical trial with
oral simvastatin was conducted using 16 patients with
asthma whereby the authors found no improvement in
asthma symptoms, pulmonary function or measures of
asthmatic inﬂammation.
28 Two other clinical trials
showed improvements in asthma symptoms, lung func-
tion and sputum eosinophil counts in subjects on
statins.
29 30 A recent study of short-term treatment with
atorvastatin in 71 smokers with asthma failed to show
improvements in lung function but may have improved
their asthma quality of life score.
31 Given the small
samples and contradicting conclusions of the above
studies, these results should be interpreted cautiously.
Stanek and colleagues
32 conducted the ﬁrst observa-
tional study using the Medco National Integrated Data-
base to explore the relationship between statin
treatment and asthma. A total of 6574 inhaled cortico-
steroid-treated adult asthmatics were studied. Statin
exposure was independently associated with a signiﬁcant
33% reduction in recurrent asthma-related hospital-
isation/ER visits over 12 months (OR, 0.67; 95% CI 0.58
to 0.76; p<0.0001). A recent study using the Taiwan
National Health Insurance Database found statin use in
patients with asthma to be independently associated with
the decreased risk of hospitalisation due to asthma (HR,
1.02; 95% CI 1.02 to 1.03; p<0.001).
33
The contradicting results between small clinical trials
and larger observational studies clearly suggest that
more studies investigating the potential role of statins in
the management of asthma are required to make any
clinical or policy-guiding decisions. The purpose of this
study was to investigate the beneﬁcial effects of statins on
asthma outcomes using the Mississippi Medicaid claims
database. The various animal model studies and clinical
trials described above show varying results and have their
own limitations. Another observational study using
a different data set is economically more feasible and
provides us with an overview of the situation in the real-
world setting. This study uses a propensity score-matched
cohort study design, which in itself should take into
account confounding effects due to the variables used to
compute the propensity scores.
34 Prior hospitalisations,
ER and ofﬁce visits due to asthma, adherence to inhaled
corticosteroid (ICS) medications and average number of
short-acting b agonists during the study period were
used to compute the propensity scores. These had not
been taken into account in the earlier observational
studies. Prior hospitalisations due to asthma and average
number of short-acting b agonists can be an indicator of
the severity of the disease, whereas non-compliance to
the medications is a potential confounder as it could
lead to hospitalisation/ER visits.
METHODS
Data source
For the purpose of the study, the 2002e2004 Mississippi
Medicaid claims data were analysed. Medicaid is
a federal programme that provides healthcare coverage
to many of the most vulnerable populations in the USA,
including low-income children and their parents, low-
income elderly, pregnant women with low family income
and the disabled poor. The claims data for each year are
comprised of a Person Summary File and four Claims
Filesdinpatient (IP), institutional long-term care (LT),
prescription drug (RX) and other services (OT). The
Person Summary File includes person-level data on
eligibility, demographics, managed care enrolment,
a summary of utilisation and Medicaid payment by type
of service. Each observation in the claims ﬁles represents
a transaction or record of the charges and payments
made to the healthcare provider for the services
rendered to the Medicaid enrollee, including details
such as the date of service, expenditures for utilised
services, associated diagnostic information and provider
and procedure type. The Person Summary File has
a record for every individual enrolled in the programme
at anytime during the year; however, the claims ﬁles may
have more than one or no records for each Medicaid
beneﬁciary depending on his/her utilisation of services.
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Statin use in asthma managementThe study was approved by the Institutional Review
Board of the University of Mississippi and use of the data
was approved by a data use agreement ﬁnalised by the
Centers for Medicare and Medicaid Services.
Study design and sample
A retrospective cohort design was utilised. The study
involved analysis of the Medicaid beneﬁciary claims from
1 January 2002 to 31 December 2004. It is important to
note that because the study period under consideration
is prior to the implementation of Medicare Part D, the
database does include prescription claims for Medicaid-
eligible patients aged 65 years and older. Asthmatic
adults above 18 years of age were identiﬁed using the
ICD9 code 493.xx, within the 18-month identiﬁcation
period starting 1 July 2002 and concluding 31 December
2003 as graphically represented in ﬁgure 1. The index
date for a particular subject in the exposed group was
any date within the identiﬁcation period, 6 months prior
to which the subject had at least one prescription for an
ICS, at least an 80% adherence rate to statins (ie,
proportion of days covered $0.8), in addition to already
having been diagnosed as having asthma. The subjects
on statin and ICS therapy were identiﬁed using the
National Drug Codes for these drugs, respectively. A total
of 589 beneﬁciaries were initially identiﬁed to be in the
exposed group. Similarly, Medicaid beneﬁciaries identi-
ﬁed as asthmatics and on ICS therapy were selected as
the unexposed population with the only difference
being that these patients were not on concurrent statin
therapy.
The study design included a washout period from 1
January 2002 to 31 June 2002 in order to track the
prescription records of patients identiﬁed and included
in the study. The 589 subjects in the exposed group were
initially matched to a pool of 7390 subjects in the
unexposed group using propensity scores (within
a range of 60.005) computed using the covariates
described later. Each exposed subject was matched to 10
corresponding subjects from the unexposed group;
following which the unexposed subjects were assigned
the index date of the exposed subjects they were
matched to. This was done in order to maximise the
number of exposed subjects that had at least two corre-
sponding subjects from the unexposed group with an
ICS prescription 6 months prior to the index date and
were eligible throughout the same period. Following
these procedures, 479 exposed subjects were obtained,
along with corresponding 958 unexposed subjects. A
detailed ﬂow diagram representing subject selection
can be found in ﬁgure 2. The two cohorts were then
followed for a period of 1 year beginning the index
date, and their outcomes in terms of asthma-related
hospitalisations and ER visits were compared.
Study variables
Covariates
The exposed and unexposed groups were matched on
age, gender, race, regions of Mississippi and Charlson
Comorbidity Index (CCI) using propensity scoring. The
age of the subjects as of 31 December 2002 was
computed. Gender was classiﬁed into male and female.
Race was grouped into three categories: Caucasians,
AfricaneAmerican and others. Additionally, subjects
were categorised into rural and urban regions of
Mississippi based on the county of residence. This vari-
able was used to serve as a surrogate indicator of the
access to care and control for differences in provider
type. The CCI was computed and used as an indicator of
additional comorbidities.
Figure 1 Graphical
representation of the study design.
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b agonists per subject, prior hospitalisations, ER visits,
ofﬁce and laboratory visits due to asthma were addi-
tionally controlled for in the analysis performed on the
matched cohorts. These could only be computed after
the unexposed subjects were assigned their index dates
and hence could not be used for the propensity score
calculations. The proportion of days covered was used as
an indication of adherence to ICS therapy and was
computed for the 6 months prior to the index date for
each subject. Short-acting b agonists are the most effec-
tive therapy for rapid reversal of airﬂow obstruction and
prompt relief of asthmatic symptoms. The average
number of short-acting b agonists per subject was
computed for 6 months prior to the index date and was
used as an indicator of the severity of the disease. The
number of hospitalisations, ER visits, ofﬁce and labora-
tory visits attributed to a primary diagnosis of asthma in
the 6-month washout period prior to the index date were
also used as indicators of the severity of the disease.
Outcome variables
Hospitalisation due to asthma was coded dichotomously
(as occurrence and non-occurrence of event), using
the principal diagnosis code for hospitalisation, through
1-year after the index date for both the exposed and
unexposed. Additionally, ER visit due to asthma was
computed in a similar manner.
Statistical analysis
Descriptive statistics were calculated for the exposed and
unexposed subjects pre- and post-matching. Means and
SDs were calculated for continuous data, whereas
percentages were used for categorical data. Differences
between exposed and unexposed groups were assessed
using t tests or c
2 tests depending on whether the vari-
able was continuous or categorical.
After the identiﬁcation of the exposed and unexposed
based on the inclusion criteria described previously,
propensity scores were calculated for the subjects in both
groups. The propensity score for an individual is deﬁned
as the conditional probability of being treated given the
individual’s covariates and thus reduces bias by
balancing the covariates in the two groups.
34 Logistic
regression was used to compute and save the probability
of being in the exposed group for all subjects based on
their age, gender, race, region and CCI as discussed
previously.
After the matched exposed and unexposed cohorts
were obtained, conditional logistic regression was used
to assess the relationship between statin use and the two
outcome variables, asthma-related hospitalisations and
ER visits.
Figure 2 Algorithm displaying the identiﬁcation of study
subjects’. ICS, inhaled corticosteroids.
Table 1 Study sample characteristics before and after matching
Characteristic
Before matching
p Value
After matching
p Value Exposed (589) Unexposed (7390) Exposed (479) Unexposed (958)
Age, mean (SD) 63.28 (612.25) 48.87 (619.17) <0.0001* 62.59 (612.13) 63.48 (612.92) 0.2124
Gender, n (%) 0.5750 0.1994
Male 125 (21.22) 1642 (22.22) 101 (21.09) 231 (24.11)
Female 464 (78.78) 5748 (77.78) 378 (78.91) 727 (75.89)
Race, n (%) <0.0001* 0.4716
White 334 (56.71) 3321 (44.94) 269 (56.16) 540 (56.37)
Black 253 (42.95) 4023 (54.44) 208 (43.42) 417 (43.53)
Other 2 (0.34) 46 (0.62) 2 (0.42) 1 (0.1)
Region, n (%) 0.0544 0.0287*
Urban 167 (28.35) 2379 (32.19) 138 (28.81) 331 (34.55)
Rural 422 (71.65) 5011 (67.81) 341 (71.19) 627 (65.45)
Charlson comorbidity
index, mean (SD)
4.01 (62.48) 2.65 (62.17) <0.0001* 3.75 (62.22) 3.48 (62.16) 0.0300*
*p<0.05.
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As discussed previously, 589 subjects met the inclusion
criteria for the exposed cohort. The pool of unexposed
subjects included 7390 individuals prior to matching on
the propensity scores. Table 1 compares the demo-
graphic characteristics among the exposed and unex-
posed cohorts before and after matching. Prior to
matching, the average age of asthma patients on
concurrent statin therapy was signiﬁcantly higher than
that of those not on statin therapy (48.87 (619.17) vs
63.28 (612.25)). A signiﬁcantly higher proportion of
asthma patients who were not on concurrent statin
therapy were AfricaneAmerican as compared with those
on statin therapy (54.44% vs 42.95%) before matching.
Additionally, those on concurrent statin therapy had
a signiﬁcantly higher average CCI than those not on
concurrent statin therapy (4.01 (62.48) vs 2.65
(62.17)).
After matching, the exposed cohort comprised of 479
individuals with 958 individuals in the unexposed
cohort. Post-matching, a signiﬁcantly higher proportion
of asthma patients on concurrent statin therapy were
from the rural areas of Mississippi (71.19% vs 65.45%;
p¼0.0287) as compared with those not on statin therapy
(table 1). Additionally, the average CCI of patients on
concurrent statin therapy was higher than that of those
not on statin therapy (3.75 (62.22) vs 3.48 (62.16);
p¼0.03), but the difference was much smaller compared
with the difference prior to matching.
The proportion of exposed and unexposed subjects
using additional medications, besides ICS, for asthma
management can be found in table 2.
Descriptive information on the covariates adjusted for
in the ﬁnal conditional logistic regression model can be
found in table 3. Subjects with asthma on concurrent
statin therapy were signiﬁcantly less adherent to their
ICS therapy (0.47 (60.27) vs 0.51 (60.28)), used lesser
number of short-acting b agonist prescriptions on an
average (2.74 (62.10) vs 3.49 (62.85)) and had fewer
ER visits due to asthma 6 months prior to the index date
(0.02 (60.14) vs 0.06 (0.29)) when compared with
subjects not on concurrent statin therapy.
The results of the conditional logistic regression
conducted on the matched data and the ORs for
hospitalisation/ER admission due to asthma among
patients on concurrent statin therapy as opposed to
those not on statin therapy are displayed in table 4.A t
least one asthma-related hospitalisation was observed in
3.79% of the subjects on concurrent statin therapy and
6.47% of the subjects not on concurrent statin therapy,
12 months after index date. At least one ER visit due to
asthma was observed in 4.18% of the subjects on
concurrent statin therapy and 9.08% of the subjects not
on concurrent satin therapy, 12 months after index date.
The odds of a hospital visit and/or ER visit due to
asthma for asthma patients on concurrent statin therapy
were almost half the odds for patients not on statin
therapy (unadjusted OR¼0.51; 95% CI (0.34 to 0.76)).
Similarly, they were also less likely to be hospitalised
(unadjusted OR¼0.56; 95% CI (0.32 to 0.98)) and visit
the ER (unadjusted OR¼0.44; 95% CI (0.27 to 0.73))
due to asthma exacerbations as opposed to those not on
statin therapy. The above ORs have not been adjusted
for additional variables such as prior asthma-related
hospitalisations, ER visits, ofﬁce and lab visits, number of
short-acting b agonist prescriptions and adherence to
ICS therapy. The adjusted conditional ORs after
accounting for these factors are also found in table 4.A
statistically signiﬁcant relationship between statin use
and the combined end point as well as asthma-related
ER visits remained after adjustment for these other
variables.
DISCUSSION
Over the 3 years of data analysed, 589 subjects met the
inclusion criteria for the exposed cohort, prior to
matching, and were classiﬁed as subjects on statin
therapy, with 7390 subjects in the unexposed cohort.
Table 2 Additional medications used for asthma
management
Medication
Exposed
(479), n (%)
Unexposed
(958), n (%)
Mast cell stabilisers 2 (<1) 5 (<1)
Leukotriene modiﬁers 134 (28) 318 (33)
Long-acting b agonists 48 (10) 126 (13)
Theophylline 42 (9) 142 (15)
Ipratropium 31 (6) 100 (10)
Short-acting b agonists 180 (38) 462 (48)
Oral corticosteroids 81 (17) 294 (31)
Table 3 Additional covariates adjusted for in the conditional logistic regression analysis
Characteristic
Exposed (479),
mean (±SD)
Unexposed (958),
mean (±SD) p Value
Adherence to ICS therapy (PDC) 0.47 (0.27) 0.51 (0.28) 0.0146*
Average no. of short-acting b agonist prescriptions per subject 2.74 (2.10) 3.49 (2.85) <0.0001*
No. of asthma ofﬁce and laboratory visits 6 months prior the index date 0.21 (0.64) 0.24 (0.65) 0.5031
No. of asthma hospitalisation events 6 months prior the index date 0.03 (0.19) 0.05 (0.24) 0.1002
No. of asthma ER events 6 months prior the index date 0.02 (0.14) 0.06 (0.29) 0.0063*
*p<0.05.
ICS, inhaled corticosteroids; PDC, proportion of days covered.
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patients on concurrent statin therapy to those not on
statins, signiﬁcant differences were observed. The
average age of the asthmatic patients on statin therapy
was signiﬁcantly higher than those not on statin therapy.
This was not surprising as patients with statin therapy
would likely have hyperlipidaemia, a condition more
prevalent in older adults. Additionally, a signiﬁcantly
higher proportion of patients on statin therapy were
Caucasian when compared with the unexposed popula-
tion and also had a higher average CCI score. In order to
control for the above differences, propensity scores were
computed and the study groups were matched on their
propensity to be in the exposed cohort.
The ﬁnal sample comprised of considerably older
subjects with the average age of the exposed and
unexposed being 62.59 (612.13) years and 63.48
(612.92) years, respectively. Most of the study subjects
were women, which is consistent with the previous
prevalence reports which indicate that asthma is more
prevalent in women in general.
35 Additionally, a higher
proportion of the sample was Caucasian, lived in rural
regions and had a considerable number of comorbid
conditions.
A higher proportion of the unexposed subjects were
on additional asthma controller therapy (table 2). It is
interesting to note, however, that the average number of
short-acting b agonist prescriptions were signiﬁcantly
higher for patients not on statin therapy, and thus, one
might expect their condition to be better managed,
which does not seem to be the case. Thus, the other way
to look at it is that their condition is more severe or is
not being managed well and hence the higher average
number of quick relief prescriptions.
A signiﬁcant reduction in the odds of hospitalisation
and ER visits due to asthma was found to be associated
with statin use. Even after controlling for the confounders
mentioned above, patients not on concurrent statin
therapy were almost twice as likely to have hospitalisation
and/or ER visits attributable to asthma when compared
with patients on statin therapy. These ﬁndings suggest
that statins are beneﬁcial in asthma management. This is
in accordance with other observational studies conducted
to investigate this relationship.
32 33
There are several limitations of this study. The
study was conducted using Medicaid claims data, and
therefore, there is a possibility of misclassiﬁcation due to
coding errors during claims processing. Further, even
though the subjects in the unexposed group were
matched to the exposed population based on their
propensity scores, signiﬁcant differences between the
two groups were still observed when compared across
their CCI scores and the region (urban vs rural) to which
they belonged. This could be attributed to two plausible
explanations. First, the cohorts were matched on
propensity scores allowing a range of 60.005. Second,
each subject was initially matched to 10 corresponding
subjects from the unexposed pool, following which two
controls were selected based on their continuous eligi-
bility throughout the study period and ICS prescription
records within 180 days prior to the index date. However,
both of the above measures were incorporated into the
study design to maximise the sample size. Even after
matching, subjects on statin therapy had a signiﬁcantly
higher average CCI score compared with those not on
statin therapy. It is unlikely that this difference could
have biased the ﬁndings towards a lower risk of hospi-
talisation due to asthma in these subjects. Another
limitation is that the population studied had an average
age of approximately 63 years and were sicker patients in
general due to the higher CCI scores, which limits the
generalisability of the study to some extent.
The ﬁndings of this study contribute signiﬁcantly to
the growing body of literature that suggests that statins
have beneﬁcial effects in preventing asthma exacerba-
tions. Some researchers suggest that the addition of
a statin to ICS therapy in clinical practice will not prove
beneﬁcial in the management of asthma referring to the
practice as a ‘snake oil panacea’.
36 However, further
investigation employing different data sets, different
methodologies and accounting for other confounding
variables which may have been overlooked is required to
provide conclusive evidence.
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Table 4 Conditional ORs of hospitalisations due to asthma associated with statin use
Outcome Unadjusted ORy, (95% CI) p Value Adjusted ORz, (95% CI) p Value
Asthma hospitalisation
and/or ER visit
0.51 (0.34 to 0.76) 0.0010* 0.55 (0.36 to 0.84) 0.0059*
Asthma hospitalisation 0.56 (0.32 to 0.98) 0.0436* 0.63 (0.35 to 1.13) 0.1183
Asthma ER visit 0.44 (0.27 to 0.73) 0.0013* 0.47 (0.28 to 0.82) 0.0069*
*p<0.05.
yAdjusted for variables used to create propensity scores.
zAdjusted for prior asthma-related hospitalisations, ER visits, ofﬁce and laboratory visits, number of short-acting b agonist prescriptions and
adherence to ICS therapy.
ICS, inhaled corticosteroid.
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